287 related articles for article (PubMed ID: 27115856)
1. NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication.
Williams PD; Chong D; Fuller T; Callanan D
Retina; 2016 May; 36(5):909-13. PubMed ID: 27115856
[TBL] [Abstract][Full Text] [Related]
2. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
[TBL] [Abstract][Full Text] [Related]
4. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
Xu Y; Tan CS
Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
[TBL] [Abstract][Full Text] [Related]
5. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes.
Goldberg RA; Shah CP; Wiegand TW; Heier JS
Am J Ophthalmol; 2014 Oct; 158(4):733-737.e1. PubMed ID: 24983791
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
7. Sequential Sterile Intraocular Inflammation Associated With Consecutive Intravitreal Injections of Aflibercept and Ranibizumab.
Grewal DS; Schwartz T; Fekrat S
Ophthalmic Surg Lasers Imaging Retina; 2017 May; 48(5):428-431. PubMed ID: 28499055
[TBL] [Abstract][Full Text] [Related]
8. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
9. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
[TBL] [Abstract][Full Text] [Related]
10. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
[TBL] [Abstract][Full Text] [Related]
11. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
12. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated With Poor Response to Aflibercept After Switching From Ranibizumab or Bevacizumab in Neovascular Age-related Macular Degeneration.
Cheng S; Leng T
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):458-65. PubMed ID: 27183550
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
15. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
Forooghian F; Albiani DA; Kirker AW; Merkur AB
Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
[TBL] [Abstract][Full Text] [Related]
16. Physician Utilization Patterns for VEGF-Inhibitor Drugs in the 2012 United States Medicare Population: Bevacizumab, Ranibizumab, and Aflibercept.
Baisiwala S; Bundorf MK; Pershing S
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):555-62. PubMed ID: 27327285
[TBL] [Abstract][Full Text] [Related]
17. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
Eadie JA; Ip MS; Kulkarni AD
Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
[TBL] [Abstract][Full Text] [Related]
18. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
Bavinger JC; Yu Y; VanderBeek BL
Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
Hall LB; Zebardast N; Huang JJ; Adelman RA
J Ocul Pharmacol Ther; 2014 May; 30(4):346-52. PubMed ID: 24552305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]